Search
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Sulfacetamide
go.drugbank.com/drugs/DB00634ApprovedAn anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.
Mixtures: Sodium Sulfacetamide and Sulfur Clarifying Wash in a Urea VehicleSynonyms: N-Acetylsulfanilamide, N-SulfanilylacetamideDifenoxin
go.drugbank.com/drugs/DB01501ApprovedIllicitDifenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). … It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide
Bismuth subgallate
go.drugbank.com/drugs/DB13909ApprovedIt is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. … internal deodorant where it is often employed as the primary active ingredient.
Human cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalThe seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. … During the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus.
Poliglusam
go.drugbank.com/drugs/DB11234ApprovedInvestigationalIn comparison, commercial poliglusam is derived from deacetylation of chitin contained in the shells of various sea crustaceans such as shrimps [L999]. … In addition, chitosan also exhibits antimicrobial and antioxidant activities.
Categories: Compounds used in a research, industrial, or household settingCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThe FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme.
Synonyms: N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamideNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]
Fosfomycin
go.drugbank.com/drugs/DB00828ApprovedInvestigational[A230348] In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring. … Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_.
Products: Fosfomycin Infectopharm 40 mg/ml Pulver für ein Konzentrat zur Herstellung einer InfusionslösungRipasudil
go.drugbank.com/drugs/DB13165InvestigationalIt was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.
Categories: Sympathomimetics in Glaucoma Therapy